Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Non-Current Liabilities (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $636708.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities rose 30.2% year-over-year to $636708.0, compared with a TTM value of $636708.0 through Sep 2025, up 30.2%, and an annual FY2024 reading of $744724.0, up 26.7% over the prior year.
  • Total Non-Current Liabilities was $636708.0 for Q3 2025 at Sunshine Biopharma, down from $706530.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.9 million in Q4 2021 and bottomed at $489027.0 in Q3 2024.
  • Average Total Non-Current Liabilities over 5 years is $724947.5, with a median of $639882.0 recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities tumbled 63.93% in 2022, then surged 38.09% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $1.9 million in 2021, then crashed by 63.93% to $685264.0 in 2022, then decreased by 14.23% to $587764.0 in 2023, then grew by 26.7% to $744724.0 in 2024, then dropped by 14.5% to $636708.0 in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SBFM at $636708.0 in Q3 2025, $706530.0 in Q2 2025, and $722199.0 in Q1 2025.